Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRHI Magnesita Regulatory News (RHIM)

Share Price Information for RHI Magnesita (RHIM)

Share Price is delayed by 15 minutes
Get Live Data
2,705.00    -25.00 (-0.92%)
Bid:
2,700.00
Ask:
2,730.00
Spread: 30.00 (1.111%)
Market Cap: £1.28b
RHIM Live PriceLast checked at - London Stock Exchange

Intraday RHI Magnesita Share Chart

Trading Update

15 Jun 2023 07:00

RNS Number : 7720C
RHI Magnesita N.V.
15 June 2023
Ā 

RHI Magnesita N.V.

("RHI Magnesita" the "Company" or the "Group")

TRADING UPDATE

Ā 

RHI Magnesita, the leading global supplier of high‐grade refractory products, systems and solutions, today provides an update on trading for the five months ended 31 May 2023 (the "Period").

Ā 

Trading update for the five months ended 31 May 2023

The momentum of improving profitability and margins delivered in Q1 2023 continued in April and May, as refractory pricing was largely maintained against a background of reducing costs.

Refractory sales volumes in the Period excluding M&A were 7% lower year on year, in line with overall market demand. Steel, cement and glass demand outside of IndiaĀ remains soft due to a slowdown in construction activity, with some glass project postponements now evident. Demand in the non-ferrous metals segment continues to be resilient. As anticipated due to the subdued demand backdrop and reducing input costs, the Group is beginning to experience sales price deflation in a number of its markets which is expected to continue and possibly accelerate through the remainder of the year.

Refractory EBITA margin contribution for the Period, which excludes vertical integration benefits, was better than expected, supported by cost deflation in April and May, as the cost of freight and purchased raw material reduced, partially offset by weaker fixed cost absorption due to lower production volumes.

The continued lower pricing environment for magnesite-based raw materials means that the Group's vertical integration EBITA margin contribution remains subdued and in line with the 1.8% of Group margin delivered in the second half of 2022.

As a result, the overall Adjusted EBITA margin for the Period was 12.1% (2022: 11.6%), delivering Unaudited Adjusted EBITA of €174 million (2022: €155 million).

Ā 

Financial position

Net debt to EBITDA remains at a similar level to the 2.1x reported at 31 March 2023, including a 12 month historic contribution from businesses acquired during the period.

Absolute net debt at 31 May 2023 was largely unchanged from 31 December 2022, supported by strong operating cashflow. The Group continues to retain significant liquidity of €1.2Ā billion.

Net Working capital (before consolidation of M&A) was down slightly from its 31Ā December 2022 level,Ā as reductions in inventory and accounts receivable were largely offset by lower accounts payable. The Group continues to prioritise security of supply for its customers in order to support recent market share gains.

Total capital expenditure in the five months to 31 May 2023 was €42 million, out of overall guidance of €200 million for 2023, with spending weighted towards the second half.

M&A increased net debt by €268 million in the first five months of the year, which was partially offset by the Qualified Institutional Placement ("QIP") by RHI Magnesita India Ltd, which raised approximately €101 million in April 2023. The QIP is to be followed by an equity investment of €22 million by the Group in RHI Magnesita India Ltd via a Preferential Issue which is expected to complete in June 2023. In the second half of the year the previously announced acquisition of Seven Refractories for a cash consideration of €95 million is expected to be completed.

Ā 

Outlook

The outlook for the Group's key end markets and consequently customer volumes remains uncertain, with the order book currently suggesting only a moderate volume increase in H2, if at all, resulting in ongoing under-absorption of fixed costs. Pricing pressure is expected to continue and possibly accelerate through the remainder of the year.

Supported by the stronger than expected performance in the first five months of the year, the Board now expects a modest outperformance on its earlier 2023 EBITA and EBITA margin guidance.

Leverage, measured as a ratio of net debt to EBITDA, is expected to remain above 2.0x as the Group further executes on its M&A pipeline.

Ā 

For further enquiries, please contact:

Chris Bucknall, Head of Investor Relations

Tel +43 699 1870 6490

E‐mail: chris.bucknall@rhimagnesita.com

Ā 

For media enquiries:

Hudson Sandler

Tel +44 020 7796 4133

E-mail: rhimagnesita@hudsonsandler.com

Ā 

About RHI Magnesita

RHI Magnesita is the leading global supplier of high-grade refractory products, systems and solutions which are critical for high-temperature processes exceeding 1,200°C in a wide range of industries, including steel, cement, non-ferrous metals and glass. With a vertically integrated value chain, from raw materials to refractory products and full performance-based solutions, RHI Magnesita serves customers around the world, with around 13,500 employees in 33 main production sites and more than 70 sales offices. RHI Magnesita intends to leverage its leadership in terms of revenue, scale, product portfolio and diversified geographic presence to target strategically those countries and regions benefitting from more dynamic economic growth prospects.

The Group maintains a premium listing on the Official list of the London Stock Exchange (symbol: RHIM) and is a constituent of the FTSE 250 index, with a secondary listing on the prime segment of the Vienna Stock Exchange (Wiener Bƶrse). For more information please visit: www.rhimagnesita.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (596/2014/EU).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Ā 
END
Ā 
Ā 
TSTNKQBNDBKBCAD
Date   Source Headline
1st Jun 20268:49 amRNSTotal Voting Rights
13th May 20264:07 pmRNSResult of AGM
1st May 20268:57 amRNSTotal Voting Rights
29th Apr 20267:00 amRNSQ1 Trading Update
1st Apr 20269:11 amRNSTotal Voting Rights
26th Mar 20262:54 pmRNSNotice of AGM
10th Mar 202611:18 amRNSDirector/PDMR Shareholding
2nd Mar 20267:55 amRNSAnnual Financial Report
2nd Mar 20267:49 amRNSTotal Voting Rights
2nd Mar 20267:00 amRNS2025 Full Year Results
13th Feb 20268:56 amRNSNotice of Results
2nd Jan 20267:00 amRNSTotal Voting Rights
2nd Jan 20267:00 amRNSTotal Voting Rights
10th Dec 20259:10 amRNSDirectorate change
10th Nov 20257:00 amRNSTrading Update
7th Nov 202511:48 amRNSDirectorate change
3rd Nov 202511:54 amRNSDirectorate change
1st Oct 20257:00 amRNSTotal Voting Rights
1st Aug 20257:00 amRNSTotal Voting Rights
30th Jul 20257:00 amRNS2025 Half Year Results
16th Jul 20257:00 amRNSNotice of Results
30th Jun 20258:29 amRNSDirector Declaration
2nd Jun 20258:53 amRNSTotal Voting Rights
29th May 20259:26 amRNSDirector/PDMR Shareholding
23rd May 20258:12 amRNSDirector Declaration
7th May 20254:11 pmRNSResult of AGM
7th May 20257:00 amRNSQ1 2025 Trading Update
1st May 20259:07 amRNSTotal Voting Rights
7th Apr 20253:36 pmRNSDirector/PDMR Shareholding
3rd Apr 20254:17 pmRNSDirector/PDMR Shareholding
1st Apr 20254:49 pmRNSDirector/PDMR Shareholding
1st Apr 20259:13 amRNSTotal Voting Rights
28th Mar 20254:12 pmRNSDirector/PDMR Shareholding
27th Mar 20253:30 pmRNSNotice of AGM
27th Mar 20252:50 pmRNSDirectorate Change
24th Mar 202512:32 pmRNSNotice of AGM
7th Mar 202510:13 amRNS2025 Long Term Incentive Plan Awards
27th Feb 20257:00 amRNS2024 Full Year Results
17th Feb 20257:00 amRNSNotice of Results
3rd Feb 20259:11 amRNSTotal Voting Rights
28th Jan 20251:59 pmRNSCompletion of Resco transaction
2nd Jan 20257:00 amRNSTotal Voting Rights
28th Nov 202410:09 amRNSDirector/PDMR Shareholding
21st Nov 20249:03 amRNSDirector/PDMR Shareholding
11th Nov 20247:00 amRNSQ3 2024 Trading Update
7th Oct 202410:10 amRNSDirector/PDMR Shareholding
1st Oct 20247:00 amRNSTotal Voting Rights
27th Sep 202411:15 amRNSExercise of LTIP options by PDMR
19th Aug 202410:31 amRNSDirector/PDMR Shareholding
12th Aug 20242:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.